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Indirect costs of inflammatory bowel diseases: Crohn’s 
disease and ulcerative colitis. A systematic review
Paweł Kawalec
A b s t r a c t 
Introduction: Crohn’s disease and ulcerative colitis are lifelong illness-
es which have a  significant impact on quality of life and personal burden 
through a reduction in the ability to work, sick leave and restrictions of lei-
sure time. The aim of this study was to conduct a systematic review of the 
indirect costs of Crohn’s disease and ulcerative colitis.
Material and methods: The search was carried out in Medline, EMBASE, the 
Centre for Reviews and Dissemination, and reference lists of identified arti-
cles and reference lists of identified articles were also handsearched. All costs 
were adjusted to 2013 USD values by using the consumer price index and 
purchasing power parity. Identified studies were then analysed in order to 
assess their heterogeneity and possibility of inclusion in the meta-analysis.
Results: Eleven of the identified publications presented indirect costs of 
Crohn’s disease or ulcerative colitis. The range of estimated yearly indi-
rect costs per patient was large, from $1 159.09 for loss of earnings to 
$14 135.64 for lost productivity and sick leave for Crohn’s disease. The val-
ues for ulcerative colitis ranged from $926.49 to $6 583.17. Because of the 
imprecise definition of methods of indirect cost calculations as well as het-
erogeneity of indirect cost components, a meta-analysis was not performed. 
Conclusions: The indirect costs of ulcerative colitis seem to be slightly lower 
than in the case of Crohn’s disease. A small number of studies referring to 
indirect costs of Crohn’s disease and ulcerative colitis were identified, which 
indicates the need to conduct further investigations on this problem.
Key words: Crohn’s disease, ulcerative colitis, indirect costs, productivity loss.
Introduction
Crohn’s disease and ulcerative colitis are two idiopathic inflammato-
ry bowel disorders. The clinical course of Crohn’s disease and ulcerative 
colitis is unpredictable, marked by alternating periods of exacerbation 
and remission. Ulcerative colitis is restricted to the colon [1], but Crohn’s 
disease can affect the entire gastrointestinal tract, from the mouth to the 
anus, and patients frequently present with abdominal pain, fever, and 
clinical signs of bowel obstruction or diarrhoea with the passage of blood 
or mucus, or both [1, 2]. 
Therapy of Crohn’s disease and ulcerative colitis is directed at quickly 
resolving symptoms and subsequently maintaining symptom-free peri-
ods. Lifelong medical treatment is required, and often innovative biologic 
therapy is necessary, which is effective in the majority of patients [3, 4] 
but expensive and difficult to achieve in many countries. 
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For many patients, Crohn’s disease imposes 
a substantial personal burden, with unpredictable 
fluctuating symptoms, time off work, the need for 
expensive drugs, or surgery and multidisciplinary 
care. With a prevalence of about 0.1% (0.007% to 
0.27% for Crohn’s disease and 0.008% to 0.35% 
for ulcerative colitis) [5] in many developed coun-
tries Crohn’s disease also places a major burden 
on public health-care resources.
Crohn’s disease and ulcerative colitis are life-
long diseases, and have a  significant impact on 
quality of life and personal burden through reduc-
tion in the ability to work, long-term and short-
term interruptions in work, restrictions of leisure 
time, and out-of-pocket expenses (e.g. travel, car-
ers). For all the above reasons the indirect costs of 
Crohn’s disease and ulcerative colitis are expected 
to have a significant role in the disease burden.
The aim of this review is to assess the indirect 
costs of Crohn’s disease and ulcerative colitis and 
to define their main components. The conclusions 
resulting from this study can constitute the basis 
for further research. 
Material and methods
Indirect costs
Indirect costs or productivity losses are the la-
bour earnings that are forgone as a  result of an 
adverse health outcome. The decreased produc-
tivity can be a result of illness, death, side effects, 
or time spent receiving treatment. Indirect costs 
include the lost earnings and productivity of both 
patients and the family members who take care 
of them. They consist of three major components: 
absence from paid work, including sick leave, ear-
ly retirement and reduced employment (or unem-
ployment) (absenteeism), reduced productivity of 
paid work (presenteeism), and reduced opportuni-
ties for unpaid activities (loss of leisure) [6]. 
Absenteeism refers to the number of days on 
sick leave, and early leaving of the labour mar-
ket due to sickness (e.g. early retirement or early 
death). Presenteeism refers to a  situation when 
a sick person is present at work but their produc-
tivity is lower than average due to disease.
Indirect costs may be difficult to quantify be-
cause of a lack of quality data, but they often rep-
resent a  significant percentage of the total cost 
associated with many diseases [7].
Each category of indirect costs can be calculat-
ed using one of two methods: the human capi-
tal approach and the friction cost approach. The 
human capital approach (HCA) converts the gross 
income which will not be obtained in the future 
due to disease into the real costs from a  social 
perspective. The HCA is based on the assumption 
that work not done due to disease is a decrease of 
human capital and is a burden to society. The fric-
tion cost approach (FCA) takes into account pro-
ductivity losses until a  new person is employed 
as a substitute for the sick one. The FCA is based 
on the assumption that society can replace a sick 
person in order to prevent productivity losses [7]. 
Literature search
A  systematic literature review was conducted 
to obtain studies concerning the indirect costs 
of Crohn’s disease and ulcerative colitis. Arti-
cles written in English, published from 1990 to 
March 2014 (cut-off date: 6th March 2014), were 
included. To include all relevant studies, a search 
of Medline (using MeSH Terms), EMBASE (using 
Emtree), and the Centre for Reviews and Dissem-
ination (CRD) databases was conducted. Search 
terms included: (inflammatory bowel disease OR 
Crohn’s OR Crohn OR (ulcerative AND (disease 
OR colitis))) AND ((indirect OR productivity OR 
economic) AND (cost OR costs OR loss OR burden 
OR (human AND capital))). No date/time/country 
filters were used. We considered original studies 
and systematic reviews as well as economic eval-
uations written in English. Records were excluded 
if they did not present any kind of indirect costs, 
or referred to illness other than Crohn’s disease or 
ulcerative colitis. Firstly, papers were excluded if 
they were not concerned with Crohn’s disease or 
ulcerative colitis, based on titles. Subsequent pa-
pers were excluded if they were irrelevant to the 
indirect costs, based on abstracts. The remaining 
papers were assessed based on full texts. Addi-
tionally, reference lists of identified studies were 
reviewed to include all relevant studies. Original 
sources of information concerning the indirect 
costs of Crohn’s disease and ulcerative colitis were 
included. Economic analysis of particular technol-
ogies, such as cost-utility studies, were excluded 
as they usually concern hypothetical groups of pa-
tients (e.g. for Markov modelling) and mostly do 
not focus on overall cost estimates. Additionally, 
abstracts and posters were excluded as they do 
not provide sufficient data and should not be in-
cluded in a systematic literature search. This sys-
tematic review was conducted in accordance with 
the PRISMA Statement to ensure a proper record 
selection process.
Synthesis of literature
All identified articles concern the indirect costs 
of inflammatory bowel disease, especially Crohn’s 
disease and ulcerative colitis. Data from eligible 
articles were collected, including the author’s 
name, publication year, reference year for cost, 
region, number of patients, study method, compo-
nents of indirect costs, and estimated indirect cost 
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per patient. In order to achieve comparability of 
results across the studies, the author attempted 
to break down the indirect expenses identified in 
particular studies into the same categories. 
In order to facilitate the comparison of data be-
tween the studies, the costs were converted into 
annual rates. If costs per patient were not provid-
ed, the appropriate values were estimated using 
data reported in the original paper. The consum-
er price index (CPI) was used to adjust costs to 
2013 values, and then all costs were converted to 
USD purchasing power parity (PPP). If the cost ref-
erence year included a range of dates, the lesser 
value was chosen.
Studies were assessed in terms of the compat-
ibility of the population, endpoints, methodology 
and presented results. All calculations were done 
using Microsoft Excel 2007 and OpenMetaAnalyst 
(for the purpose of meta-analysis).
Estimates of the indirect costs of inflamma-
tory bowel disease were also presented, as the 
majority of the participants in these studies have 
Crohn’s disease or ulcerative colitis.
Results
In summary, 166 titles concerning the indirect 
costs of Crohn’s disease or ulcerative colitis were 
identified in Medline, 161 in EMBASE, and 40 in 
CRD. After eliminating repetitive records, 280 pa-
pers were submitted for further assessment. Of 
these, 40 full articles were included in the final 
evaluation. As a result, 11 papers (full text publica-
tions) were incorporated into this review (Figure 1). 
Although all references from previously identified 
records were reviewed, no additional sources were 
identified (other than already found). 
We identified 4 studies presenting indirect 
costs associated with Crohn’s disease [8–11], 
4 studies for both Crohn’s disease and ulcerative 
colitis [12–15], and 3 studies concerning inflam-
matory bowel disease in general [16–18], from the 
following countries: Italy [8], New Zealand [10], 
Germany [12], United Kingdom [13], Spain [9], 
Canada [18], Sweden [11, 16], and United States 
of America [14, 15, 17]. Our systematic review 
showed that most of the data on Crohn’s disease 
and ulcerative colitis came from Europe. 
The major components of indirect costs were: 
lost productivity due to leaving work earlier be-
cause of the disease, absence from work due to 
sick leave, early retirement or mortality (absen-
teeism), and loss of leisure time for nonemploy-
ees (loss of leisure). A  few studies also included 
costs of travel, carers, additional phone or internet 
requirements, or special diet, but the above cost 
categories are not indirect costs. Only one study 
concerned presenteeism, and none of them con-
cerned unemployment (Tables I and II). 
This review included cost assessments from 
North America and European countries, and New 
Zealand. In the United States the yearly indirect 
costs per patient of Crohn’s disease and ulcer-
ative colitis including absenteeism were assessed 
to be $6 434 and $7 264, respectively. When only 
short-term disability was included, the costs were 
much lower, and amounted to $1 963 and $1 673, 
respectively. Indirect costs assessed in European 
countries seem to be higher than in the United 
States. Indirect costs resulting from lost produc-
tivity were $5  128–14  136 for Crohn’s disease 
and $6  583 for ulcerative colitis. It should be 
mentioned that more studies with cost data were 
identified for European countries than for North 
American countries, and the above conclusion 
may change when new studies are conducted.
One study carried out in the United States 
presented total indirect costs for both Crohn’s 
disease and ulcerative colitis. The values ranged 
from $1 877 to $3  754 (work disability). In the 
review we also included three studies which con-
cerned inflammatory bowel disease in general. 
One was carried out in Europe (Sweden), one in 
Canada, and one in the United States. The highest 
indirect cost ($7 442) was calculated in the Unit-
ed States, and was due to work loss, whereas the 
corresponding value for Canada was more than 
six times smaller. The European study included the 
indirect cost of inflammatory bowel disease in the 
Figure 1. PRISMA flow diagram showing the record 
selection process. Reason A – secondary data; rea-
son B – different population; reason C – different 
endpoint; reason D – other
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form of sickness leave and early retirement, and it 
was comparable to the cost assessed in Canada.
The results presented above indicate that the 
highest component of indirect costs was loss of 
productivity. 
Only the indirect costs that have the same com-
ponents measured by the same approach, the same 
population, and endpoints presented as mean and 
standard deviation can be incorporated into the 
meta-analysis. Almost all the identified studies 
reported the numbers of patients used to obtain 
indirect cost data. In the study by Blomqvist et al. 
there was only information about national total in-
direct costs. Only in three studies was the method-
ology for the estimation of indirect costs specified, 
and these studies were included in further analysis 
[8, 10, 12]. The study by Lion et al. [10] was ex-
cluded from further research as it includes a slight-
ly different population – paediatric and perianal 
Crohn’s disease patients. The remaining two stud-
ies included patients with Crohn’s disease, and the 
study by Stark et al. [12] also reported results for 
ulcerative colitis patients. The results of the study 
by Benedini et al. [8] are presented as total indirect 
costs, without the values for each cost category. 
Stark et al. [12] presented their results in the form 
of short- (sick leave) and long-term productivity 
losses. Taking into account the methodology of 
the studies [8, 12] listed above, and therefore the 
heterogeneity of the studies identified, there was 
no possibility to carry out a meta-analysis.
Discussion
Several studies were identified concerning sys-
tematic reviews of the indirect costs of inflam-
matory bowel disease. In a study by Cohen et al. 
[19] a systematic review of the costs of ulcerative 
colitis was conducted. No data were collected for 
Crohn’s disease. The authors included only full 
texts; abstracts were excluded from the review. All 
the identified studies were carried out in Europe 
or North America; no studies from New Zealand 
were identified. In a  study by Yu et al. [20] only 
the costs of Crohn’s disease were collected. The 
methodology and identified studies were similar 
to those in the review by Cohen et al. Abstracts 
and studies beyond North America and Europe 
were not included in the review. The above re-
views were conducted in 2006–2008 and do not 
include studies from later, e.g. Benedini [8] or Lion 
[10]. Also, one study published in 2003 by Juan et al. 
[9] was not included in the identified reviews, but it 
was described in another review by Odes [21].
Indirect costs identified in this review varied 
considerably because of the difference in compo-
nents. Expenses such as loss of earnings due to 
leaving work earlier, or sick leave, have a  minor 
impact on total indirect expenditures.
The author made an attempt to perform a me-
ta-analysis, but taking into account the differenc-
es in the studies’ methodology, variety of report-
ed end points and population it was impossible 
to carry out. In the majority of studies there was 
no information about the method of indirect cost 
estimation. Different studies take into account 
different combinations of indirect cost categories, 
and there were also differences in the definitions 
of each category. The above deficiencies and prob-
lems need to be resolved in order to improve the 
decision making process based on the indirect 
costs of Crohn’s disease and ulcerative colitis. 
Indirect costs are very difficult to assess, mainly 
because of a  lack of comprehensive data sources 
and difficulties in measurement. For example, one 
study included presenteeism, which is the reduction 
of workers’ effectiveness due to illness. Only two 
studies included loss of leisure time for non-employ-
ees as a part of indirect costs. Lion et al. [10] exam-
ined the effect of Crohn’s disease on costs resulting 
from travel, carers, tutors, and additional phone 
and internet requirements, but these cost catego-
ries cannot be treated as indirect costs. Also, Bassi 
et al. [13] assessed the influence of inflammatory 
bowel disease on out-of-pocket expenses such as 
travel, prescription charges, special diets, and cloth-
ing, which are not indirect costs. It is proved that 
patients with Crohn’s disease have a  higher mor-
tality risk than the general population [1]. Neverthe-
less, none of the identified studies included the cost 
resulting from increased mortality and hence lost 
productivity. The above indicates that the identified 
costs may have been underestimated.
In conclusion, Crohn’s disease and ulcerative 
colitis impose a substantial personal burden and af-
fect the ability to work. The observation concerning 
the influence of the disease on patients’ functional 
abilities requires special attention in future studies 
on Crohn’s disease and ulcerative colitis. The great 
variety of methodologies and indirect cost compo-
nents in studies revealed that it is impossible to 
carry out a meta-analysis. This review showed that 
further research is needed due to the lack of infor-
mation on the topic, and a precise methodology of 
indirect cost estimation must be developed.
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